Denali Therapeutics (DNLI) Assets (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Assets data on file, last reported at $1.3 billion in Q1 2026.

• Assets for Q1 2026 came in at $1.3 billion, changed 0.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 billion (changed 0.42% YoY), and the FY2025 annual result was $1.1 billion, down 16.69% from the prior year.
• Assets climbed to $1.3 billion in Q1 2026 per DNLI's latest filing, from $1.1 billion in the prior quarter.
• Over five years, Assets peaked at $1.6 billion in Q1 2024 and troughed at $1.1 billion in Q3 2025.
• A 5-year average of $1.3 billion and a median of $1.3 billion in 2022 frame the typical range for Assets.
• The sharpest annual moves came in 2024 and 2025: Assets gained 19.09% in 2024, then declined 27.4% in 2025.
• A 5-year view of Assets shows it stood at $1.5 billion in 2022, then fell by 20.98% to $1.2 billion in 2023, then grew by 19.09% to $1.4 billion in 2024, then dropped by 16.69% to $1.1 billion in 2025, then gained by 10.58% to $1.3 billion in 2026.
• Business Quant data shows DNLI's Assets at $1.3 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.1 billion in Q3 2025.